Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario
SAGA Metals Commences Diamond Drilling at the Wolverine Heavy Rare Earth Element Project in Labrador - First Two Diamond Drill Holes Intersected Prospective REE-Bearing Volcanic Unit
RETRANSMISSION: QIMC Reports Record 30.0% Clean Natural Hydrogen at 413 Metres as Pressurized Free Gas Observations Trigger Repeated Hydrogen Alarms at Bennett Hill, Nova Scotia
